Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Curis: Q3 Earnings Snapshot

Curis: Q3 Earnings Snapshot

CRIS : 3.98 (+1.27%)
Curis: Q2 Earnings Snapshot

Curis: Q2 Earnings Snapshot

CRIS : 3.98 (+1.27%)
Curis: Q1 Earnings Snapshot

Curis: Q1 Earnings Snapshot

CRIS : 3.98 (+1.27%)
Curis: Q4 Earnings Snapshot

Curis: Q4 Earnings Snapshot

CRIS : 3.98 (+1.27%)
Curis: Q3 Earnings Snapshot

Curis: Q3 Earnings Snapshot

CRIS : 3.98 (+1.27%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 3.98 (+1.27%)
Curis to Present at Upcoming Healthcare Conferences in September

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4...

CRIS : 3.98 (+1.27%)
Curis: Q2 Earnings Snapshot

Curis: Q2 Earnings Snapshot

CRIS : 3.98 (+1.27%)
Curis Provides Second Quarter 2023 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...

CRIS : 3.98 (+1.27%)
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...

CRIS : 3.98 (+1.27%)

Barchart Exclusives

2 Energy Dividend Stocks to Buy This November for Growth and Income
For investors seeking steady gains, these two dividend-paying energy stocks could be smart picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar